Please assess the completion status of the following clinical trial:

Trial Title: Liposomal Doxorubicin in Treating Patients With Stage IIB, Stage IVA, or Stage IVB Recurrent or Refractory Mycosis Fungoides

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed mycosis fungoides~  * Stage IIB, IVA, or IVB~* Refractory or recurrent disease after at least 2 of the following prior therapies:~  * Local and/or systemic steroids~ * Retinoids~ * Interferon alfa~ * Local carmustine~ * Systemic chemotherapy~ * Psoralen and ultraviolet A (PUVA) light therapy~* No CNS involvement~* No erythroderma (T4)~PATIENT CHARACTERISTICS:~Age~* Over 18~Performance status~* Karnofsky 60-100%~Life expectancy~* Not specified~Hematopoietic~* Neutrophil count at least 1,500/mm\^3~* WBC at least 2,000/mm\^3~* Platelet count at least 75,000/mm\^3~* Hemoglobin at least 10 g/dL~Hepatic~* Bilirubin no greater than 1.5 times upper limit of normal (ULN)~* SGOT and SGPT no greater than 2.5 times ULN~Renal~* Creatinine no greater than 1.5 times ULN~Cardiovascular~* LVEF normal by echocardiography or radionuclide angiocardiography~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for at least 2 years after study participation~* No psychological, familial, sociological, or geographical condition that would preclude study compliance or follow-up~* No active infection requiring specific therapy (e.g., antibiotics or anti-HIV therapy)~* No other prior or concurrent primary malignant tumor except adequately treated carcinoma in situ of the cervix or squamous cell or basal cell skin cancer~PRIOR CONCURRENT THERAPY:~Biologic therapy~* See Disease Characteristics~* More than 2 weeks since prior immunotherapy~Chemotherapy~* See Disease Characteristics~* Prior systemic chemotherapy allowed provided all of the following conditions are met:~  * Cumulative anthracycline dose is less than 200 mg/m\^2~ * No allergy to anthracyclines~ * Prior methotrexate is low dose (i.e., weekly dose less than 30 mg)~* More than 2 weeks since prior chemotherapy~Endocrine therapy~* See Disease Characteristics~* No concurrent systemic steroids~Radiotherapy~* More than 2 weeks since prior radiotherapy~Surgery~* Not specified~Other~* Recovered from toxic effects of prior therapy, excluding alopecia~* No other concurrent anticancer therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Caelyx (Type: EXPERIMENTAL): doxorubicin HCl liposome IV over 1 hour on days 1 and 15. Treatment repeats every 28 days for up to 6 courses.

Based on this trial design, predict the completion outcome and termination type (if applicable).